- 4009 Hackney Springs Ln, Sachse, TX 75048
Your Lab May Be Losing Money Right Now!
Find out fast with a
No-Cost Revenue Audit.
Washington MCED reimbursement remains an emerging space with no immediate coverage. The federal Nancy Gardner Sewell Act, signed February 2026, creates a Medicare benefit pathway beginning in 2028, but only for FDA‑approved tests none currently qualify. Pending state bills HB 1062 and SB 5642 could shape future commercial and Apple Health policies but are not yet law. Today, most payers classify MCED screening as investigational.
Labs should verify benefits before testing, use the correct PLA or unlisted CPT codes, document elevated risk rather than routine screening, and obtain prior authorization for complex panels. Denials require payer‑specific policy review, strong clinical documentation, and when applicable, external review through Washington’s Office of the Insurance Commissioner. A Washington lab billing partner, like TransLabs, can track evolving rules, manage appeals, and keep emerging‑test claims clean to protect your revenue while coverage policies develop.
While running a Washington laboratory and trying to bill for multi-cancer early detection (MCED) testing, you’re navigating a landscape that’s moving fast but hasn’t fully landed yet. There are a lot of rumors, and some of these are completely different from the facts. So let’s clear the confusion.
A federal law now exists that opens the door to Medicare coverage. Washington lawmakers have proposed (but not yet passed, as of August 2026) new coverage mandates. And commercial payers are, for the most part, still treating MCED tests as investigational. It’s too early to expect Washington MCED reimbursement rate changes around mandates and revise billing, as it can lead to claim denials and patient frustration.
Want to stay current with rules and recover revenue from claims? This blog guides you through that. Let’s discover the facts, pending rules, and best practices to optimize your laboratory revenue cycle through Washington laboratory billing services.
The MCED tests are blood draws that hunt for tiny fragments of tumor DNA (circulating tumor DNA (ctDNA) assays) floating around the bloodstream. Instead of screening for one cancer at a time, a single sample gets checked against dozens of cancer types at once. It’s an exciting piece of lab science, and it’s why so many FDA-approved multi-cancer tests are in the pipeline.
However, as of this writing, no MCED test has received full FDA approval. The best-known products on the market, including GRAIL’s Galleri test, currently run as laboratory-developed tests under Clinical Laboratory Improvement Amendments (CLIA) certification rather than as FDA-cleared devices.
| Code Type | Test Covered | Billing Details |
|---|---|---|
| PLA codes (four digits + "U") | Test-specific, proprietary lab assays like MCED panels | Sole-source or licensed labs only; payer-specific coverage varies wildly |
| Unlisted CPT (e.g., 81479) | Novel molecular tests without an assigned PLA code | Almost always triggers manual review and higher denial rates |
| DEX Z-Codes | Used by many MolDX-participating MACs and some commercial plans for lab-developed tests | Registration is required before claims will even process |
It’s important to note that a PLA code alone doesn’t guarantee payment. It only means the test has a specific identifier. Whether it’s paid for depends entirely on the payer’s medical policy, and right now, most commercial and Medicaid plans still classify MCED screening as investigational for patients without symptoms.
On February 3, 2026, H.R. 842, or the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, was signed into law as part of the Consolidated Appropriations Act, 2026. This is a huge deal for the industry, so let’s break down exactly how it impacts billing.
Considering that, this test:
However:
So, if a patient walks in asking whether Medicare will pay, the answer is that it doesn’t do that currently. But a legal pathway now exists that should open coverage once a test wins FDA clearance, which is likely not earlier than 2028.
House Bill 1062, Washington’s biomarker testing coverage bill, would require state-regulated commercial health plans, the Public Employees Benefits Board, and the Health Care Authority (for Medicaid) to cover biomarker testing when it’s backed by FDA labeling, a Medicare national or local coverage determination, or recognized clinical guidelines.
If it’s signed, it becomes a useful law for oncology and molecular labs. But as of August 2026, HB 1062 has not passed. It cleared a public hearing in the House Health Care & Wellness Committee back in January 2025, got reintroduced for the 2026 session by resolution, and has been awaiting decision in committee ever since without a floor vote. It is proposed legislation, not current law.
Now, here is something important for your lab billing process. Don’t mention HB 1062 as an enforceable mandate in your appeals letters or payer negotiations, as it’s not official. Position it instead as a bill worth tracking, and reference the already existing coverage criteria, such as FDA labeling, CMS coverage determinations, or peer-reviewed guidelines, to build a strong medical necessity case today.
Senate Bill 5642 is aimed at improving maternal health and cancer screening performance metrics for the clients of Apple Health, Washington’s Medicaid agency. Like HB 1062, it remains awaiting final decision in the Senate Health & Long-Term Care Committee as of this year and hasn’t been enacted. It’s more of a quality-metrics bill for Managed Care Organizations (MCOs) than a direct billing mandate, but it signals where state priorities are headed for Medicaid cancer screening access.
| Coverage Layer | Current Status | What It Means for MCED Billing |
|---|---|---|
| Federal Medicare (Nancy Gardner Sewell Act) | Signed into law Feb 2026; coverage pathway opens 2028 | No current Medicare payment for MCED screening; plan for a future launch |
| WA no-cost preventive services law (amended by ESHB 2242, signed March 2026) | Active | Ties state-regulated plan coverage to USPSTF/HRSA recommendations as of June 30, 2025. MCED isn't on that list yet, so it doesn't qualify as a no-cost preventive benefit today |
| HB 1062 biomarker mandate | Pending, in committee | Watch it, don't cite it as binding |
| SB 5642 Medicaid screening metrics | Pending, in committee | Signals future MCO priorities for Apple Health cancer screening |
| Commercial payer medical policies | Mostly "investigational" for asymptomatic screening | Expect prior authorization requirements and denials without strong documentation |
Since most commercial carriers still rely on investigational or experimental coverage denials for MCED and complex biomarker panels, your front-end documentation makes or breaks the claim. A few things that consistently move the needle:
Don’t skip prior auth just because it’s a hassle. A denied claim costs your lab far more staff time than the authorization request ever would.
Here’s the practical appeal sequence labs should follow:
Also note that the OIC’s authority covers fully-insured commercial plans regulated by the state. It doesn’t have jurisdiction over self-funded employer plans (which fall under federal ERISA rules) or Medicare claims. Know which bucket your patient’s coverage falls into before you build the appeal strategy.
For labs billing Washington Apple Health, a few practical points matter beyond the pending SB 5642 metrics bill:
Getting paid for emerging tests like MCED panels comes down to a smart and proactive approach. To secure your reimbursement:
However, all that might drain your staff’s time and energy. Tasks, such as denial appeals, prior auth tracking, and payer credentialing, consume hours that your lab could spend on patient results instead. This is all possible if you outsource laboratory billing and coding services to a reliable partner like TransLabs, which works with Washington labs every day on such emerging-test billing complexities, from PLA code setup to OIC appeal support. With that, your team isn’t left guessing which rules are live and which are still bills awaiting decision in committee.
Washington’s MCED reimbursement picture is promising, just not fully written yet. The federal groundwork is in place, state lawmakers are clearly paying attention, and payer policies will keep shifting as clinical evidence builds. But for labs billing today, the smart move is grounding every claim in what’s actually enforceable right now, not what might pass next session.
Keep your documentation complete, know your appeal processes, and watch the legislative calendar without compromising your revenue cycle on it. That’s how Washington labs stay ahead of a coverage landscape that’s evolving month by month.